OTCMKTS:KHTRF Knight Therapeutics (KHTRF) Stock Price, News & Analysis → Elon’s New Device is About to Shock the World (From InvestorPlace) (Ad) Free KHTRF Stock Alerts $4.39 0.00 (0.00%) (As of 05/17/2024 ET) Add Compare Share Share Today's Range$4.39▼$4.3950-Day Range$3.88▼$4.3952-Week Range$3.20▼$4.39Volume4,400 shsAverage Volume7,136 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice Target$7.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartHeadlinesShort InterestStock AnalysisAnalyst ForecastsChartHeadlinesShort Interest Knight Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside70.8% Upside$7.50 Price TargetShort InterestBearishDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.68 out of 5 stars 3.5 Analyst's Opinion Consensus RatingKnight Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageKnight Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Knight Therapeutics' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares ShortedShort Interest Ratio / Days to CoverKnight Therapeutics has a short interest ratio ("days to cover") of 82, which indicates bearish sentiment.Change versus previous monthShort interest in Knight Therapeutics has recently increased by 2.03%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldKnight Therapeutics does not currently pay a dividend.Dividend GrowthKnight Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for KHTRF. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for Knight Therapeutics this week, compared to 0 articles on an average week. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Knight Therapeutics insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 24.85% of the stock of Knight Therapeutics is held by institutions.Read more about Knight Therapeutics' insider trading history. Previous Next N/A Earnings and Valuation Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaThe Overlooked Retirement Asset You Probably Don’t Own4 out of 5 Americans believe we’re on the brink of a retirement crisis. Luckily, in these unprecedented times, we have an unprecedented solution. Once considered a “fringe” investment, the crypto market is now taking the world by storm.Click here to access the Crypto Retirement Blueprint now. About Knight Therapeutics Stock (OTCMKTS:KHTRF)Knight Therapeutics Inc. develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma. The company provides Ladecvina for multiple myeloma and myelodysplastic syndrome, mantle cell lymphoma, and follicular lymphoma; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Rembre for chronic myeloid leukemia; Palbocil for breast cancer; Ambisome and Cresemba for fungal infection; Impavido for leishmaniasis; Dolufevir for HIV infection; Exelon for dementia; and Ibsrela for irritable bowel syndrome with constipation. In addition, it offers Salofalk for ulcerative colitis; Ursofalk for biliary cirrhosis; Imvexxy for moderate to severe dyspareunia; Bijuva for vasomotor symptoms; Fibridoner for idiopathic pulmonary fibrosis; Toliscrin DPI for pseudomonas aeruginosa lung infection; Toliscrin 1-2 for severe acute or resistant chronic infections; and Tobradosa Haler for chronic lung infections. Further, it finances other life science companies; and invests in life sciences venture capital funds. The company was incorporated in 2013 and is headquartered in Montreal, Canada.Read More KHTRF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart KHTRF Stock News HeadlinesMay 12, 2024 | finance.yahoo.comKnight Therapeutics First Quarter 2024 Earnings: Revenues Beat Expectations, EPS LagsMay 9, 2024 | finance.yahoo.comKnight Therapeutics Up Near 3% After Announcing Supply and Distribution Agreement For ADHD Medication; Despite Mixed Q1May 9, 2024 | globenewswire.comKnight Therapeutics Reports First Quarter 2024 ResultsMay 9, 2024 | globenewswire.comKnight Therapeutics Enters into Exclusive Supply and Distribution Agreement with Ironshore Pharmaceuticals & Development, Inc. for JORNAY PM® for Canada and Latin AmericaMay 8, 2024 | globenewswire.comKnight Therapeutics Inc. announces voting results from the Annual General MeetingMay 7, 2024 | finance.yahoo.comKnight to Present at the 2024 RBC Capital Markets Global Healthcare Conference in New York CityMay 2, 2024 | globenewswire.comNotice of Knight Therapeutics' First Quarter 2024 Results Conference CallMarch 28, 2024 | finance.yahoo.comKnight Therapeutics Inc. ranks on The Globe and Mail’s fifth-annual Women Lead Here benchmark of executive gender diversityMarch 24, 2024 | finance.yahoo.comKnight Therapeutics Inc. Just Missed Earnings With A Surprise Loss - Here Are Analysts Latest ForecastsMarch 21, 2024 | globenewswire.comKnight Therapeutics Reports Fourth Quarter and Year-End 2023 ResultsMarch 14, 2024 | baystreet.caKnight Therapeutics Inc.March 14, 2024 | globenewswire.comNotice of Knight Therapeutics' Fourth Quarter and Year End 2023 Results Conference CallMarch 6, 2024 | realmoney.thestreet.comKnight Therapeutics price target raised by C$0.50 at Raymond JamesFebruary 28, 2024 | globenewswire.comKnight Therapeutics Inc. Celebrates its First Decade of SuccessFebruary 21, 2024 | globenewswire.comKnight Therapeutics Announces Regulatory Submission of Fostamatinib in BrazilFebruary 4, 2024 | finance.yahoo.comKnight Therapeutics Inc.'s (TSE:GUD) top owners are retail investors with 43% stake, while 23% is held by private companiesJanuary 31, 2024 | finance.yahoo.comG2S2 CAPITAL INC. ANNOUNCES INCREASED INVESTMENT IN KNIGHT THERAPEUTICS INC.November 12, 2023 | markets.businessinsider.comRBC Capital Keeps Their Buy Rating on Knight Therapeutics (KHTRF)November 11, 2023 | markets.businessinsider.comKnight Therapeutics: Strong Q3 Results and Positive Outlook Drive Buy RatingNovember 9, 2023 | msn.comKnight Therapeutics reports Q3 resultsNovember 2, 2023 | finance.yahoo.comNotice of Knight Therapeutics' Third Quarter 2023 Results Conference CallOctober 30, 2023 | finance.yahoo.comKnight Therapeutics (TSE:GUD) investors are sitting on a loss of 44% if they invested five years agoOctober 3, 2023 | prnewswire.comKnight Therapeutics Inc. ocupa el puesto 90 en la quinta clasificación anual de The Globe and Mail de Canada's Top Growing Companies.October 3, 2023 | prnewswire.comKnight Therapeutics Inc. ocupa a 90ª posição no quinto ranking anual das Empresas de Maior Crescimento do Canadá (Canada's Top Growing Companies) segundo a The Globe and Mail.September 29, 2023 | finance.yahoo.comExecutive Chairman of Knight Therapeutics Jonathan Goodman Buys More StockSee More Headlines Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolOTCMKTS:KHTRF CUSIPN/A CIKN/A Webwww.gud-knight.com Phone(514) 484-4483FaxN/AEmployees725Year FoundedN/APrice Target and Rating Average Stock Price Target$7.50 High Stock Price Target$7.50 Low Stock Price Target$7.50 Potential Upside/Downside+70.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Key ExecutivesMr. Jonathan Ross Goodman B.A. (Age 55)L.L.B., M.B.A., Executive Chairman Comp: $183.38kMs. Samira Sakhia BCom (Age 56)CA, CPA, MBA, President, CEO & Director Comp: $492.75kMr. Arvind UtchanahChief Financial OfficerMs. Amal Khouri B.Sc.M.B.A., Chief Business OfficerMr. Jeff MartensGlobal Vice President of CommercialMr. Stephani SaverioVice President of Business DevelopmentMr. Leopoldo BosanoVice-President of Manufacturing & OperationsMs. Monica PercarioGlobal Vice President of Scientific AffairsMr. Henrique DiasGlobal Director of MarketingMs. Susan Caroline EmblemGlobal Vice President of Human ResourcesMore ExecutivesKey Competitors1933 IndustriesOTCMKTS:TGIFF4Cable TV InternationalOTCMKTS:CATV4Front VenturesOTCMKTS:FFNTFAB ScienceOTCMKTS:ABSCFAbacus Health ProductsOTCMKTS:ABAHFView All Competitors KHTRF Stock Analysis - Frequently Asked Questions Should I buy or sell Knight Therapeutics stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Knight Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" KHTRF shares. View KHTRF analyst ratings or view top-rated stocks. What is Knight Therapeutics' stock price target for 2024? 1 Wall Street research analysts have issued 12 month price targets for Knight Therapeutics' shares. Their KHTRF share price targets range from $7.50 to $7.50. On average, they predict the company's share price to reach $7.50 in the next year. This suggests a possible upside of 70.8% from the stock's current price. View analysts price targets for KHTRF or view top-rated stocks among Wall Street analysts. How have KHTRF shares performed in 2024? Knight Therapeutics' stock was trading at $3.96 at the beginning of the year. Since then, KHTRF stock has increased by 10.9% and is now trading at $4.39. View the best growth stocks for 2024 here. How do I buy shares of Knight Therapeutics? Shares of KHTRF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:KHTRF) was last updated on 5/18/2024 by MarketBeat.com Staff From Our PartnersObama’s Forever Term [exposed]Porter & CompanyCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaMissed NVDA? Buy this AI stock NOWChaikin AnalyticsMost important medical advance in 100 yearsThe Oxford ClubThe Presidential candidate you should REALLY be worried aboutStansberry ResearchForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressShocking: One AI startup's revenue could surge 4,735%Manward Press Adding Choose a watchlist: Watchlist My Default Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.